GT Biopharma, Inc.

Amendment
CIK: 0000109657·Biotechnology·DELAWARE·Filed: Jul 23, 2020
Total Offering

Indefinite

Amount Sold

$5,607,000

Investors

18

First Sale

Apr 20, 2020

Offering Details

Type
Debt, Other: Debt convertible into equity.
Exemptions
Rule 506(b)
Entity Type
Corporation
Non-Accredited Investors
No

Related Persons

NameRole
Anthony Cataldo
Related Person
Steven Weldon
Related Person

Company

GT Biopharma, Inc.

9350 Wilshire Blvd., Suite 203

Beverly Hills, CA, 90212

800-304-9888

SEC Filing

0001654954-20-007958

View on SEC EDGAR

Want deeper insights?

Sign up for free to search all filings, track companies, and set up alerts.

Sign Up Free